If you grew up in the Midwest like I did, 4-H would be about the best strawberry jam and the handsomest looking hog at the state fair. But Deborah Madden, Associate Extension Agent for Arlington, says, The program really reflects what area you live in. Locally the kids are surrounded by defense and the government. We dont have an agriculture program here. She explains that in Fairfax they still do a lot of animal science and horses.

But she says that when they did a survey of 4-H summer camp participants the youth said they wanted to learn about agriculture in Virginia which is the number one industry in the state. So they are going to bring the Virginia State University mobile agriculture van to summer camp this year where the campers will be able to walk in and learn about agriculture in Virginia.

Sharon Toth, 4-H Youth Extension Agent for Alexandria says the 5-day overnight summer camp at Front Royal is the biggest event they do. There will be 200 youth from the northern Virginia area participating in canoeing, yoga, archery, high ropes and this year performing arts. It will be technology free and will concentrate on leadership, teamwork and self motivation.

Madden says the 4-H core values of learning self-reliance, to be a good citizen and life skills have always been the same over time; its just that the programs are designed to fit the environment. For instance, in Arlington they have programs in recreation centers and schools that focus on things like urban gardening, culinary education and STEM. She adds they are rebuilding programs on entomology and embryology where they will hatch chickens from eggs.

Barcroft Elementary has an after school club focusing on water and air quality. She says they also have a military club at Henderson Hall that concentrates on STEM. This club has also included creative writing, aviation and cooking. The youth director decides.

Madden says, Currently I am still working with Williamsburg Middle School on Teen Cuisine, a six-week program offered during extended day. It looks at nutrition. She recalls the chicken bite salsa. Were also looking at sugary snacks, good and bad fat. Next they will head into embryology and then a gardening program.

We plan to have a full 4-H Club at Drew Elementary in two months, then Carlyn Springs library in the fall with drop in activities for teens.

Id like to test the waters on a teen club. Were missing out on the biggest opportunity in this age group.

In Alexandria Toth says they are working in recreation centers and schools to rebuild programs. Currently there are two clubs, one focusing on wellness and adventure at John Marshall Library and the other focusing on nature and animals at Billy Ford Nature Center. All it takes to set up a 4-H club is an adult mentor to serve as a leader and positive role model and with a topic the youth have an interest in. The programs are youth-driven to instill leadership. And when kids are busy, they are less likely to engage with drugs.

She remembers she was in a traditional 4-H program in New Jersey. It had the same goals, same focus on youth leadership. 4-H is designed to fit its environment.

Toth says she would really like to start a dog training club how to take care of your animal, the different breeds. I think it would really do well in Alexandria. They really love their dogs.

She adds that Gabriella Coussens Douglas MacArthur Elementary School in (4th grade) Alexandria recently won a blue ribbon for her project on entomology at the 4-H Fairfax County Contest Day. It focuses on the importance of insects and why they are important to the ecosystem.

In Arlington blue ribbon winners included: Landon Gould (10), Taylor Elementary1st place Presentations; 1st place, Extemporaneous Speaking; 2nd place, Share-the-fun. Meridian Nilles (9), Oakridge Elementary1st place, Table Setting; 1st place, Extemporaneous Speaking. Annabelle Cunningham (12), Gunston Middle School, 1st place Table Setting. Samien Chowdhury (11), Barcroft Elementary1st place, Presentations; 1st place Extemporaneous Speech.

These winners will advance to the Northeast District Contest in Spotsylvania, Va. on April,15, 2023. Toth says 4-H programs are open to kids age 5-19.

Embryology

PINNACLE FERTILITY ANNOUNCES THE PROMOTION OF BETH … – PR Newswire

March 31, 2023 medical

SCOTTSDALE, Ariz., March 29, 2023 /PRNewswire/ -- Pinnacle Fertility (Pinnacle), the nation's fast-growing physician-led fertility care platform, is proud to announce the promotion of Beth Zoneraich to Chief Executive Officer (CEO) of Pinnacle Fertility. Beth brings over two decades of experience in scaling businesses and unparalleled expertise in fertility practice innovation and development. Under Beth's leadership, the Pinnacle team will be able to catalyze the transformation of patient care, outcomes, and experience across the Pinnacle network.

Jerry Rhodes, Executive Chairman - Pinnacle Fertility, said, "Beth's appointment as our CEO allows us to leverage her exceptional skills and expertise to steer Pinnacle Fertility's expansion worldwide. We are excited about the future of fertility healthcare and are confident that Beth's vision, integrity, and leadership will be instrumental in our team's success."

Beth joined Pinnacle Fertility as Chief Operating Officer in October 2021, concurrently with the acquisition of Advanced Fertility Care, where she had served as Co-Founder and CEO. At Pinnacle, Beth pioneered the Pinnacle Embryology School in collaboration with the Medical, Lab, and Business Leadership Boards. Alongside Dr. John Jain of Santa Monica Fertility, Beth has assisted in the expansion of Pinnacle's third-party reproduction services through the launch of Pinnacle Surrogacy and Pinnacle Egg Bank. These key partnerships and operational improvements have been essential to Pinnacle's tremendous growth.

Beth Zoneraich remarked, "At Pinnacle Fertility, we are passionate about helping families experience the miracle of parenthood. I joined Pinnacle for its commitment to a patient-first vision and a collaborative, physician-led approach. By setting the gold standard in fertility medicine and prioritizing exceptional patient experiences and successful outcomes, we are poised for significant growth. I am honored to work alongside this compassionate and talented team."

Pinnacle Fertility encompasses 34 top-tier fertility clinics and comprehensive fertility service providers across the nation. The Pinnacle network boasts some of the top 100 fertility clinics in the country, renowned for their innovation, success, and dedication to compassionate, patient-centric care.

About Pinnacle Fertility

Pinnacle Fertility is a patient-first, physician-led fertility care platform, supporting high-performing fertility clinics and comprehensive fertility service providers nationwide. Under a united mission of fulfilling dreams by building families, Pinnacle clinics offer innovative technology and processes, compassionate patient care, and comprehensive fertility treatment services, ensuring families receive a high-touch experience on their path to parenthood.

For more information about Pinnacle Fertility, visit pinnaclefertility.com.

Contact:Walt Conrad[emailprotected]

SOURCE Pinnacle Fertility

Read this article:
PINNACLE FERTILITY ANNOUNCES THE PROMOTION OF BETH ... - PR Newswire

Embryology

Delay in early development of the embryo associated with likelihood of miscarriage – News-Medical.Net

March 31, 2023 medical

Embryos in pregnancies that end in miscarriage take longer to develop in the womb than those in pregnancies that result in live births, according to new research published today (Monday) in Human Reproduction, one of the world's leading reproductive medicine journals.

For the first time, researchers in The Netherlands have been able to look at the way embryos develop while pregnancies are ongoing. They used state-of-the-art imaging technology, including 3D ultrasound with high resolution transvaginal probes and virtual reality techniques, to create 3D holograms of the embryo.

This enabled them to assess the overall development of the embryo, including arms and legs, the shape and length of the brain and the curvature of the embryo. 3D ultrasound and virtual reality techniques also enabled them to measure embryonic volume and the distance between the crown of the head and the bottom of the embryo's buttocks (crown-rump length).

Dr Melek Rousian, a gynecologist at Erasmus MC, University Medical Center, Rotterdam, The Netherlands, who led the study, said: "We found that in the first ten weeks of the pregnancy, embryos in pregnancies that end in a miscarriage took four days longer to develop than babies that did not miscarry. We also found that the longer it takes for an embryo to develop, the more likely it is to miscarry.

"In the future, the ability to assess the shape and development of embryos could be used to estimate the likelihood of a pregnancy continuing to the delivery of a healthy baby. This would enable health professionals to provide counseling to women and their partners about the prospective outcome of the pregnancy and the timely identification of a miscarriage. This would be particularly useful for couples who have had previous pregnancies that have ended in miscarriage; we might be able to indicate the risk of another miscarriage or maybe offer some early reassurance."

The researchers collected data from women taking part in the ongoing Rotterdam Periconception Cohort (PREDICT study), a large prospective study embedded in patient care in the department of obstetrics and gynecology at Erasmus MC, University Medical Center, Rotterdam. A total of 611 ongoing pregnancies and 33 pregnancies ending in a miscarriage were included from women recruited to the study between 2010 and 2018 when they were between seven and ten weeks pregnant.

To study the internal and external characteristics and measurements of an embryo, known as embryo morphology, the ability to see the embryo in 3D is important. The researchers used virtual reality to create holograms to look at the embryos' development and they compared the morphology against established stages of embryo development, known as the Carnegie Stages.

Without the aid of 3D and virtual reality, it is far more difficult to examine the development of the embryo. For instance, the 3D virtual reality technology makes it much easier to see the development of the arms and legs. In the Carnegie staging system, the curvature and position of the arms and legs have an important role. Many historic studies have examined the products of miscarriage, but this is the first time we have been able to look at the developing pregnancy while the pregnancy was still intact."

Dr Carsten Pietersma, first author of the study, PhD candidate and ultrasonographer at Erasmus MC

The Carnegie stages of embryonic development cover the first ten weeks of gestation and run from 1 to 23. Compared to an ongoing pregnancy, a pregnancy ending in a miscarriage was associated with a lower Carnegie stage and the embryo would reach the final Carnegie stage four days later than an embryo from a pregnancy that resulted in a healthy baby. A delay in Carnegie stage increased the likelihood of a miscarriage by 1.5% per delayed stage.

After the tenth week there is no staging system for embryo development, and so the researchers used foetal growth and birth weight to assess development thereafter. They found that a pregnancy ending in a miscarriage was linked to a shorter crown-rump length and smaller embryonic volume.

"We are able to show a significant association between miscarriage and a delay in the early development of the embryo, even if the miscarriage was after ten weeks of gestation," said Dr Pietersma.

The researchers adjusted their analyses to take account of factors that could affect pregnancy outcomes such as whether or not the women had been pregnant previously, age, ethnicity, socio-economic status, alcohol use, smoking and use of folic acid or other vitamin supplements.

A limitation of the study is that it includes a relatively small number of pregnancies that ended in miscarriage from a group of women attending tertiary care hospital for preconception and prenatal care and so they may not be representative of the general population. Results of genetic testing following a miscarriage were not available to the researchers, so they do not know if the embryos that miscarried had abnormal chromosome numbers, which could have contributed to the non-viability of the pregnancies.

Dr Denny Sakkas is Chief Scientific of Boston IVF (USA) and the embryology specialist deputy editor of Human Reproduction. He was not involved with the study. He said: "The emotional burden of a miscarriage is incredibly high for women with established pregnancies. This novel study by Carsten Pietersma and colleagues examines the development of embryos in the womb and finds differences in pregnancies that end in miscarriage compared to those that result in live births. The stages of development are calculated from examination of holograms generated from state-of-the-art 3D ultrasound imaging and virtual reality. Use of this technology could prepare patients for an early adverse pregnancy outcome, possibly allowing them to obtain supportive care in case of an adverse outcome."

Source:

Journal reference:

Pietersma, C. S., et al. (2023). Embryonic morphological development is delayed in pregnancies ending in a spontaneous miscarriage. Human Reproduction. doi.org/10.1093/humrep/dead032.

Read this article:
Delay in early development of the embryo associated with likelihood of miscarriage - News-Medical.Net

Embryology

Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of – EIN News

March 31, 2023 medical

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (Rumi), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic screening platform, announced the appointment of Allen Fienberg, Ph.D., as Chief Executive Officer (CEO) and Chairman of the Board of Directors.

Our human organoid-based high throughput drug discovery platform has already identified multiple molecules and targets warranting further development, said Ali H. Brivanlou, Ph.D., co-founder of Rumi Scientific, and the Robert and Harriet Heilbrunn Professor and head of the Laboratory of Synthetic Embryology at The Rockefeller University. Having reached this point, it became clear that a CEO with expertise in advancing preclinical programs to clinical-stage candidates was needed to drive our continued progress. Allens extensive neuroscience research and drug development experience positions him ideally to lead the advancement of our lead program in Huntingtons disease (HD) and of our earlier-stage programs in autism spectrum disorder and Alport syndrome. On behalf of the Rumi Scientific team, I am pleased to welcome Allen to the Company and look forward to its ongoing evolution under his leadership.

Dr. Fienberg joined Rumi after serving for more than 20 years as Vice President of Business Development at Intra-Cellular Therapies, Inc. (ITI), which he co-founded in 2002. While at ITI, he was responsible for all business development activities along with various preclinical science initiatives. As a co-founder Dr. Fienberg also participated in early-stage fundraising, investor relations, legal and various administrative functions. From 1999-2001, Dr.Fienberg was a staff scientist at the Genomics Institute of the Novartis Research Foundation and was appointed a Research Assistant Professor at The Rockefeller University from 2001-2002. Dr.Fienberg earned his A.B. degree in Genetics from the University of California, Berkeley, and his Ph.D. in Human Genetics from Yale University. He completed post-doctoral studies at The Rockefeller University under the direction of the late Dr.Paul Greengard from 1991-1999.

What attracted me to Rumi was their highly innovative, phenotype-based drug discovery capabilities based on their unique high throughput organoid screening platform, said Dr. Fienberg. The platform evaluates drug-induced changes in phenotypes observed in neural organoids, rather than employing the traditional approach of identifying targets against which molecules are then tested. The platform has already identified molecules with the potential to impact several underlying pathological processes in HD. The platform is adaptable to almost any disease and thus has tremendous potential. I look forward to working with the talented team at Rumi to advance this and other potential therapeutic candidates.

About Rumi ScientificRumi Scientifics mission is to identify and develop novel therapeutics for rare and neurodegenerative diseases by employing its revolutionary synthetic human tissue platform to produce more predictive data leading to a safe and faster clinical trial process. The Companys lead program is an orally available bromodomain-containing protein 9 (BRD9) inhibitor in lead optimization for the treatment of Huntingtons disease. Founded in 2016, Rumi licensed foundational technology from The Rockefeller University developed by co-foundersAli H. Brivanlou, Ph.D., and Eric D. Siggia, Ph.D. For more information on Rumi Scientific, please see http://www.rumiscientific.com or contact info@rumiscientific.com.

Rumi Scientific:Allen Fienberg, Ph.D.Chairman and Chief Executive Officerallen@rumiscientific.com

Fred Etoc, Ph.D.Chief Scientific Officerfred@rumiscientific.com

Investors:Burns McClellan Lee Roth / Cameron Radinoviclroth@burnsmc.com / cradinovic@burnsmc.com

View original post here:
Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of - EIN News

Dermatology

CU School of Medicine Resident Helped to Create Inclusive … – University of Colorado Anschutz Medical Campus

March 31, 2023 medical

As a medical student interested in a career in dermatology, Nneamaka Ezekwe, MD, quickly realized that the textbooks particularly the collections of images of various skin conditions known as atlases didnt include photos of people with skin like hers.

Kodachrome is the word we use to describe pictures of disease that are used as a supplemental learning aid to trainees, says Ezekwe, now adermatologyresident at theUniversity of Colorado School of Medicine. These atlases have great kodachromes of diseases in lighter skin complexions. Erythema, which means redness of the skin, can be easily perceived in a lighter skin tone but may be harder to perceive and can be a subtle finding in darker skin tones. There is a spectrum of skin tones. My darker complexion is one skin tone, and there are complexions representative of Hispanic Latinos and people from the Middle East you cant box everybody into one bubble and say, This is what it looks like. We need to show the whole spectrum.

After Ezekwe graduated from medical school at the University of Mississippi and began working as a research fellow at the Henry Ford Department of Dermatology in Detroit, Michigan, she was excited to be part of an effort to create a more inclusive atlas that includes kodachromes of such conditions as vitiligo, hidradenitis suppurativa, and sarcoidosis in an array of different skin tones.

We tried to stay away from the conventional skin scale that we use as dermatologists, because it was never meant to categorize skin color. It was only supposed to be used as a scale of how easily people can burn or tan, Ezekwe says. Its not an accurate measurement of your skin complexion or the spectrum of skin colors.

For their book, The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas, editors Misty Eleryan, MD, MS, and Adam Friedman, MD, compiled more than650 images of more than 85 commonly seen dermatological conditions in an array of skin tones. Displayed side by side, the images are intended to advance education among health care practitioners and to visually teach them to recognize various skin conditions in different skin tones.

The book was released in August 2021, and the publisher sent a free copy to every trainee in every dermatology department in the country. The editors also created a free online database of inclusive dermatology images to which providers can refer.

As a research fellow, Ezekwe says, she was in the right place at the right time to be picked to work on the atlas project. She was one of the principal photographers who contributed images of various skin conditions to the book.

They picked departments of dermatology across the country that are known to have patients with a plethora of skin colors, she says. Henry Ford is a well-known dermatology department that tends to see a multitude of diverse patients because of its geographic location and the providers who are there. The editors reached out to us and said, Would you be interested in working on this atlas?

"My job was to find the patients in clinic, verify diagnosis with the provider, adequately consent,and take professional, studio-style pictures. From there, we would submit pictures and receive feedback by an in-house medical photographer weekly. We would meet regularly with the editors and advisory council to review cases and provide feedback as needed.

It was surprisingly easy to get patients to participate, she says, as many understood how photos of their conditions could help dermatologists make diagnoses in a population that has barriers to treatment. Many patients from ethnic backgrounds underrepresented in medicine have a distrust of the health care system, Ezekwe says, and many feel they arent treated with respect when they go to see a doctor. Compound those factors with conditions that are more difficult to detect in darker skin, and potentially dangerous skin conditions can get misdiagnosed or never diagnosed at all.

It's fairly easy to get shuffled around in the health care system, and then a diagnosis that could have been made in two months is now delayed to six years, she says. Patients from different ethnic groups want to serve as teachers so that their experience doesnt happen to other patients. I received that comment from many patients when I was taking their pictures.

The Full Spectrum of Dermatology is currently being used in her program at the CU School of Medicine, Ezekwe says, and she hears regularly from residents and other trainees across the country about how useful the atlas has been in their training.

'The Full Spectrum of Dermatology' was released in 2021.

The positive feedback, she says, shows that the atlas is slowly achieving its goal of making dermatology more equitable and inclusive.

Obviously, one atlas cant address disparities of health care in general, she says, but I do think this atlas can help to bridge the gap in helping to train providers to make common diagnoses. Even for primary care doctors, if they were able to pick up even one diagnosis that they didnt know, but they now know because they saw it in a book, that can help that patient, and in certain cases, lower their threshold to refer for further management to a dermatologist.

Turn Biotechnologies Introduces its Dermatology Platform to the … – Yahoo Finance

March 31, 2023 medical

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the international regenerative aesthetic community.

Vittorio Sebastiano, Turn Biotechnologies co-founder and head of research, will share research data at the Aesthetic and Anti-aging World Congress on Friday.

Evidence-based data showing the global regenerative efficacy of Turn Bio's Epigenetic Reprogramming of Aging (ERA) technology on human skin cells will be shared at the Aesthetic and Anti-aging World Congress, the leading international conference specializing in aesthetic regenerative and anti-aging medicine.

Turn Bio's co-founder and head of research Vittorio Sebastiano, PhD, will provide insights on stem cell exhaustion and discuss how the company's ERA technology can rejuvenate cells and restore cellular function in skin. The workshopwill take place on March 31, from 9 a.m. to 10:30 a.m. CET in the Camille Blanc Auditorium at the Grimaldi Forum in Monaco.

The latest Turn Bio dermatology data will also be discussed in presentations by several dermatology key opinion leaders during scientific sessions chaired by internationally recognized experts in the field.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA platform technology, ERA (Epigenetic Reprogramming of Aging), restores optimal gene expression by combatting the effects of aging in the epigenome. This restores cells' ability to prevent or treat disease and heal or regenerate tissue. It will help to fight incurable chronic diseases. Its eTurnaDelivery Platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types.

The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see http://www.turn.bio.

Story continues

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroupjim@rightstorygroup.comor (312) 543-9026

(PRNewsfoto/Turn Biotechnologies, Inc.)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/turn-biotechnologies-introduces-its-dermatology-platform-to-the-european-aesthetic-community-at-amwc-301785512.html

SOURCE Turn Biotechnologies, Inc.

Turn Biotechnologies Introduces its Dermatology Platform to the ... - Yahoo Finance

Dermatology

AAD Posters Address Misconceptions, Concerns Regarding … – AJMC.com Managed Markets Network

March 31, 2023 medical

A majority of research has shown that biosimilars are highly similar to their originator product in terms of safety and efficacy. Two posters presented at the American Academy of Dermatology (AAD) annual meeting evaluated misconceptions about biosimilars in the dermatology community and addressed concerns around the use of biosimilars in psoriasis with a review of the data.

The first poster reviewed the biosimilar approval process to clarify misconceptions that dermatologists have about biosimilars.1 Dermatologists have approached biosimilar medicines with caution, the researchers wrote.

A recent Cardinal Health report2 corroborated the sentiment that dermatologists are hesitant to switch to biosimilars. According to the report, only 31% of dermatologists considered themselves very familiar with biosimilars compared with 81% of gastroenterologists, 76% of rheumatologists, and 36% of ophthalmologists. Dermatologists were also the most likely compared with the other specialists to say they were not very familiar (13%).

The authors of the AAD poster used a PubMed search to identify studies on the molecular design, preclinical and clinical testing requirements, and approval processes of biosimilars. They described how the complexity of biologics means that even batches of innovator biologics can vary during preclinical testing.

Biosimilars undergo strict preclinical testing and must demonstrate near-similarity to the current originator product in quality factors such as receptor binding and pharmacokinetics, the researchers explained.

While clinical testing is less stringent for a biosimilar compared with the originator product, the purpose of the clinical testing is to confirm the safety and efficacy of the biosimilar. Then, the use of extrapolation allows for biosimilars to be approved for all indications of the originator product without further testing. As a result, the emphasis of biosimilar product testing is on preclinical rather than clinical testing, the authors noted.

Physicians who recognize that biologics are too complex to duplicate, and who desire indication-specific clinical data on biosimilars, might be satisfied knowing biosimilars provide more evidence of similarity than we have for different batches of the innovator product, they concluded. Regulations that are more stringent for biosimilars than for different batches of innovator products may not be logical.

In the second poster, the researchers addressed concerns about the use of biosimilars approved to treat psoriasis using extrapolated evidence from other diseases.3

The researchers compared efficacy/effectiveness, safety, and drug survival of biosimilars to treat plaque psoriasis with originator products. They used data from 13 randomized controlled trials (RCTs) and 3 cohort studies. Of the RCTs, 10 were for adalimumab, 2 were etanercept, and 1 was infliximab. Of the cohort studies, 1 was adalimumab, 1 was etanercept, and 1 was both etanercept and infliximab.

There were 11 trials that compared biosimilars with the originator in patients who had never been on the originator product (initiators), and 9 trials analyzed switching from the originator product to the biosimilar (switchers). The initiator trials all had similar rates of 75% improvement in Psoriasis Area and Severity Index, as well as similar adverse events (AEs) by week 16 and the switched trials also had similar outcomes by week 52.

One of the cohort studies reported more AEs among the group of adalimumab patients switching from originator to the biosimilar, although the other 2 cohort studies showed no significant differences in safety and effectiveness.

The majority of available evidence suggests similarities between biosimilars and originators, the researchers concluded. Future pharmacovigilance studies are needed to evaluate the long-term, real-world use of biosimilars for psoriasis treatment.

References

1. Patel P, Purvis C, Hamid R, Feldman S. Biosimilars in dermatology: understanding testing and addressing misconceptions. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans, LA. Poster 41465. https://eposters.aad.org/abstracts/41465

2. 2023 Biosimilars Report. Cardinal Health. February 22, 2023. Accessed March 28, 2023. https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-biosimilars-report-2023.pdf

3. Phan DB, Warren RB, Lunt M, Yiu ZZN. Biosimilars in the treatment of psoriasis a systematic review of evidence from randomized controlled trials and real-world data. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans, LA. Poster 42621. https://eposters.aad.org/abstracts/42621

Link:

AAD Posters Address Misconceptions, Concerns Regarding ... - AJMC.com Managed Markets Network

Dermatology

5 Perspectives on Laser Treatment in Dermatology – Dermatology Times

March 31, 2023 medical

Interested in finding out what is new, trending, and up-and-coming in the world of laser therapy in dermatology? Review these 5 articles from the Maui Derm Hawaii 2023 conference coverage earlier this year.

/AdobeStock

Suneel Chilukuri, MD, discussed a Maui Derm Hawaii 2023 session called Lasers and Energy Devices Used to Treat Medical Problems Whats New in 2023. In the session, a group of experts, including Chilukuri, discussed using lasers and other similar devices to treat dermatologic conditions such as acne, cutaneous lesions, scars, and pigment disorders.

Lawrence Eichenfield, MD, discussed the use of several laser and laser-based therapies for the treatment of acne vulgaris in adolescents at his Maui Derm Hawaii 2023 session.

Several current laser therapy options for acne include blue light, pulsed dye laser, Nd: YAG (long-pulsed, Q-switched, combination), erbium laser resurfacing therapies, intense pulsed light, photodynamic therapy, solid-state fractional 589/1319 nm laser, and 1726-nm laser systems.

Ilona Frieden, MD, discussed the future of laser treatments in port wine stains at her Maui Derm Hawaii 2023 session.

"Part 3 of my talk relates to a remarkable revolution that happened in medicine. And that's the advent of next-generation sequencing, which allowed us to begin to unravel the genomics of so many disorders including port wine stain birthmarks. That occurred in the past 2 decades, but mostly starting around 2010, Frieden said. What happened with that was that we had really no idea what caused them, we knew it must be some developmental error that caused this process of the blood vessels not forming correctly. But that was about it. We knew the causes of the vast majority of them, we do know the causes, and that was a real revelation.

David Laub, MD, discussed the use of laser treatment in cosmetic procedures in his Maui Derm Hawaii 2023 session Whats My Treatment.

In the session, Laub and a panel of experts discussed several real-world patient cases. Dermatologists in the surgical and aesthetic spaces assessed each case to determine which treatment (energy-based devices, lasers, fillers, injectables, topical medications) would be recommended. Then, the panelists revealed which treatment was used and why.

The second case could be in the same arena pigmentation, where a different colleague will go and maybe treat it with lasers or some other device, the same particular problem so that the audience can get a very strong sense of the different modalities that can be used for a particular problem, whether it be pigmentation, wrinkles, or reversing sun damage, in the form of texture, Laub said.

Suzanne Kilmer, MD, discussed the future of laser and energy-based devices in dermatologic treatment in her Maui Derm Hawaii 2023 session Lasers, Lights, Radiofrequency, Photodynamic Therapy and More.

We also talk about acne and ways to target acne with lasers, that's a booming field right now, Kilmer said. There are new lasers in the 1720 nanometer range that target the sebaceous glands because they have fat in them and that wavelength is absorbed by fat. So that's kind of a big newer one that's coming out.

More here:

5 Perspectives on Laser Treatment in Dermatology - Dermatology Times

Dermatology

Making Connections Between Psychiatry and Dermatology – Psychiatric Times

March 31, 2023 medical

Various studies encounter a psychiatric condition in 1 out of 3 dermatology patients. In collaboration with Dermatology Times, Psychiatric Times connected with George Kroumpouzos, MD, PhD, FAAD, a dermatologist who combines psychodermatology with clinical and cosmetic dermatology in his practice.

In this episode of An Appointment With, Kroumpouzos discusses the connections between psychiatric and dermatologic conditions, as well as the ways psychiatrists and dermatologists can work together to help patients with psychiatric and dermatologic comorbidities.

Dr Kroumpouzos is director of GK Dermatology, a clinical associate professor of dermatology at Brown University, and a professor of dermatology and collaborator at Jundia Medical School in So Paulo, Brazil.He combines clinical, cosmetic, and psychodermatology in his practice.

See the original post:

Making Connections Between Psychiatry and Dermatology - Psychiatric Times

Dermatology

Dermatology Associates of Rochester on Top Workplaces 2023 list – Democrat & Chronicle

March 31, 2023 medical

Gregory Burnett| Rochester Democrat and Chronicle

Laura Hellaby, human resources director for Dermatology Associates of Rochester, spoke about her workplace.

Its a unique practice because it is value-driven no position within the company is more important to the organization than another.

Our leadership prides itself on having an open-door policy where they encourage and are interested in innovative ideas or ideas from any team members on how to improve efficiency or process, Hellaby said. This feedback is then used to help make sure the practice is always improving, innovating, and actively working to be the best in all areas of service. However, we also stand out from other places because of the variety in which we can offer our patients a transformative, one-stop location for all things dermatology related.

Dermatology Associates is a fast paced, collaborative, and energetic workplace. Management stresses the need to foster this environment by encouraging open communication.

We seek to enrich the lives of our patients, employees, and community members through the delivery of unparalleled, individualized care with attention to health, wellness, and education, Hellaby said.

2023 Rochester Top Workplaces: 2023 Rochester Top Workplaces: Complete list of all 79 winners

More: Heres how Rochester's Top Workplaces were determined for 2023

Ensuring team members are equipped with tools for success is always vital to productivity.

This Top Workplace invested in additional education opportunities for its workers. Initiatives include lunch-and-learn-enrichment days and retreats. A system called one-on-one meetings brings together staff to discuss challenges, set goals, and run through practice scenarios.

Many benefits are available for employees to enjoy.

We typically invest over $40,000 per year on continuing education opportunities because we know how important it is to continue their development, Hellaby said. Our staff [members] have the opportunity to receive and experience wrinkle-reducing treatments, dermal filler, laser, and CoolSculpting treatments multiple times throughout the year a perk worth $5,000 to $15,000 per person. Our staff [members] typically receive around $125,000 worth of complimentary cosmetic treatments. Our clinical team enjoys a four-day work week. We also offer a full benefits package, including medical, dental, vision, life insurance, an employee assistance program, and a 401(k) plan with employer contribution. Having a work/ life balance is promoted consistently. We want people to come to work happy and leave happy. Our one-on-one meeting is essential because it gives employees a platform to address their issues.

Read the original here:

Dermatology Associates of Rochester on Top Workplaces 2023 list - Democrat & Chronicle